Navigation Links
VIA Pharmaceuticals Complies With NASDAQ Rules
Date:3/27/2009

SAN FRANCISCO, March 27 /PRNewswire-FirstCall/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced, in compliance with NASDAQ Marketplace Rule 4350(b)(1)(B), that the independent audit report included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2008 and filed with the Securities and Exchange Commission on March 27, 2009 contained explanatory paragraphs relating to the Company's ability to continue as a going concern. The disclosure in this press release is required under the above NASDAQ rule and does not represent any change to the Company's Annual Report on Form 10-K filed on March 27, 2009 with the Securities and Exchange Commission.

The Company also announced today that, as expected, it received a deficiency letter dated March 24, 2009 from NASDAQ Staff notifying the Company that as a result of the death over the March 21st weekend of Richard L. Anderson, an independent director and member of the Company's Audit Committee, Compensation Committee and Nominating and Governance Committee, the Company's Board of Directors is no longer comprised of a majority of independent directors and the Company's Audit Committee is no longer comprised of at least three independent directors, as required for continued listing by NASDAQ Marketplace Rules 4350(c)(1) and 4350(d)(2)(A), respectively. In accordance with NASDAQ Marketplace Rules, the Company has until September 17, 2009 to regain compliance with the NASDAQ listing standards. The Board of Directors of the Company intends to identify candidates to replace Mr. Anderson and appoint a new director who satisfies the independence requirements of the NASDAQ Marketplace Rules prior to September 17, 2009.

About VIA
'/>"/>

SOURCE VIA Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Anadys Pharmaceuticals to Present at Future Leaders in the Biotech Industry
2. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at BioCentury Publications Inc. Future Leaders in the Biotech Industry Conference in New York on April 2, 2009
3. Trubion Pharmaceuticals, Inc. Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Systemic Lupus Erythematosus (SLE)
4. Isis Pharmaceuticals to Present at the 4th Annual Citi Biotech Day
5. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results
6. Stallergenes Signs an Exclusive Partnership Agreement With Solvay Pharmaceuticals for the Promotion and Distribution of its Products in Russia and the CIS*
7. Arena Pharmaceuticals Obtains Equity Financing Commitment of Up to $50 Million
8. Nereus Pharmaceuticals Initiates ADVANCE, a Randomized Phase 2 Clinical Trial of NPI-2358 in Non-Small Cell Lung Cancer
9. The Need for Safe and Affordable Biopharmaceuticals Drives the Development of the European Biosimilars Market, Says Frost & Sullivan
10. Endo Pharmaceuticals Extends Subsequent Offering Period for Indevus Shares Until 5:00 pm EDT on Wednesday, March 18, 2009
11. Lexicon Pharmaceuticals 2008 Annual Report to Stockholders Available Online
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... Through science fairs, workshops, kits for building optical ... organizations will continue their work to increase awareness about ... daily life with the aid of SPIE Education ... countries, are the first of two groups of recipients ... international society for optics and photonics , in 2013. ...
(Date:5/21/2013)... , May 21, 2013 The ... and Transplant Association) is the biggest congress in ... therapy. Nearly 10,000 participants are in Istanbul ... latest research findings. New pioneering studies have been presented: ... FERRIC PYROPHOSPHATE (SFP) ADMINISTERED VIA HEMODIALYSATE REDUCES ESA USE" ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 Smarter Security, ... security solutions, today announced that Genzyme, a Sanofi company ... of Door Detective® CL for a multi-use facility in ... in four other Genzyme buildings, this latest order underscores ... the tailgate detection device improving doorway access ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 Many have ... as contributor to acne. Recently physicians from Clinical ... mental stress on the skin, and suggested using ... reduce the chemicals produced from stress that cause acne. ... the negative feelings acne brings about, stress causes changes ...
Breaking Biology Technology:Learning About Light: Education Outreach Projects Funded in 10 Countries Through First Round of SPIE Grants 2Learning About Light: Education Outreach Projects Funded in 10 Countries Through First Round of SPIE Grants 3ERA-EDTA CONGRESS 2013: Late Breaking Clinical Trials 2ERA-EDTA CONGRESS 2013: Late Breaking Clinical Trials 3Door Security at Genzyme, a Sanofi Company, Enhanced with Door Detective from Smarter Security 2Door Security at Genzyme, a Sanofi Company, Enhanced with Door Detective from Smarter Security 3Adult Acne Treatment, Probiotic Action Explains How Hypnotherapy and Probiotics May Cure Various Skin Conditions 2
... law in New Jersey could be sign of things ... about workplace violence,is nowhere more acute than among healthcare ... to become the target of on-the-job violence than,their counterparts ... of horrific headlines, healthcare facilities understandably face,mounting pressure to ...
... RICHMOND, Va., July 9 Insmed Inc. (Nasdaq:,INSM), a ... Glover, President Insmed Therapeutics, will present at the,Collins Stewart ... 10:30 AM ET, in New York., The conference ... New,York City, from Tuesday, July 8 through Thursday, July ...
... -- Dr. Fernando Perez-Ruiz Joins Ardea,s Inflammatory Disease Scientific ... ... Ardea Biosciences, Inc.,(Nasdaq: RDEA ) today announced that it has ... RDEA806 in gout,patients with hyperuricemia. Gout, also known as metabolic arthritis, ...
Cached Biology Technology:Healthcare Industry Faces Mounting Pressure to Prevent On-The-Job Violence, Says Veteran Safety and Health Attorney 2Insmed to Present at Collins Stewart Fourth Annual Growth Conference 2Ardea Biosciences' Advances RDEA806 Into Phase 2a Proof-of-Concept Study for Gout 2Ardea Biosciences' Advances RDEA806 Into Phase 2a Proof-of-Concept Study for Gout 3Ardea Biosciences' Advances RDEA806 Into Phase 2a Proof-of-Concept Study for Gout 4
(Date:5/17/2013)... 18, 2013) The AGA Research Foundation announced a ... relationship between the gut microbiota, one of today,s most ... , The AGA Research Awards Panel selected Andrew ... General Hospital and Harvard Medical School, Boston, as the ... Chan will receive $25,000 of funding, commencing in July ...
(Date:5/17/2013)... New Jersey, and City University of New York have ... that effectively clears organisms to be viewed under microscopes. ... which is one of the few high-quality clearing solutions ... Drug Enforcement Administration (DEA) due to its use as ... vital for viewing organisms under a microscope. Without them, ...
(Date:5/17/2013)... the interaction of a group of proteins in the ... identified a new target that could increase cell survival. ... School of Biochemistry and published in the EMBO ... eventually lead to new therapies for stroke and other ... by the team which identified a protein, known as ...
Breaking Biology News(10 mins):New gut microbiome research to explore red meat -- colorectal cancer pathway 2New formula invented for microscope viewing, substitutes for federally controlled drug 2New formula invented for microscope viewing, substitutes for federally controlled drug 3SUMO wrestling cells reveal new protective mechanism target for stroke 2
... is available in Spanish . , ... nematodes could improve the delivery, timing and use of ... machine is the result of a cooperative research and ... and Southeastern Insectaries, Inc., of Perry, Ga. The ...
... The Association for Molecular Pathology (AMP) opposed the ... the subject matter of a cancer-related proteonomics patent application ... submitted to NIH in response to a request for ... of Exclusive License: The Development of a Companion Diagnostic ...
... has no effect on the presence of large mammals in ... time compares the biological diversity of ecotourism zones with that ... biodiversity of areas that are not officially protected yet are ... to promote ecological tourism at the end of the 1980,s ...
Cached Biology News:Special delivery: Nematode-infected insect cadavers 2AMP opposes exclusive licensing of NIH proteomics patent 23 researchers in the Amazon clear up doubts as to the benefits of ecotourism 23 researchers in the Amazon clear up doubts as to the benefits of ecotourism 3
... for whole-blood clinical diagnostic work in hospitals ... this analyzer makes precise glucose measurements of ... lactate measurements of whole blood, plasma, or ... allows you to have glucose results expressed ...
... Cleanroom-grade vinyl curtains or ... powder-coated steel support frame to ... cleanroom that meets cleanliness to ... HEPA filter/fan units, lights, and ...
... BioSafe room is configured specifically for ... chemical analysis. Panels are precision-joined to ... to wipe down and disinfect. One-inch ... panel design creates strong, rigid surface ...
... The Varian 500-MS LC Ion Trap ... high-throughput LC/MS analysis where sensitivity, reliability ... 500-MS provides a robust platform for ... mass resolution, and mass stability reflect ...
Biology Products: